Verapamil in treatment resistant depression: A role for the P-glycoprotein transporter?

Human Psychopharmacology

Volumn 24, Issue 3, 2009, Pages 217-223

  Clarke, Gerard ^a,b   O'Mahony, Siobhain M ^a,b   Cryan, John F ^a,b   Dinan, Timothy G ^a,b  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Antidepressant; Mechanism of action; P glycoprotein; Treatment resistant depression; Verapamil

Indexed keywords

GLYCOPROTEIN P; IMIPRAMINE; SODIUM CHLORIDE; VERAPAMIL; CALCIUM CHANNEL BLOCKING AGENT; TRICYCLIC ANTIDEPRESSANT AGENT;

ANIMAL EXPERIMENT; ARTICLE; BLOOD BRAIN BARRIER; BLOOD SAMPLING; BRAIN REGION; BRAIN STEM; CONTROLLED STUDY; DEPRESSION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG MECHANISM; DRUG POTENTIATION; FRONTAL CORTEX; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; RAT; ANIMAL; BLOOD; BRAIN; DRUG ANTAGONISM; DRUG EFFECT; HISTOLOGY; METABOLISM; METHODOLOGY; SPRAGUE DAWLEY RAT; TISSUE DISTRIBUTION;

ANIMALS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BRAIN; CALCIUM CHANNEL BLOCKERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; IMIPRAMINE; MALE; P-GLYCOPROTEIN; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION; VERAPAMIL;

EID: 67649726888     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.1008     Document Type: Article

References (44)

1. Adlersberg S, Toren P, Mester R, Rehavi M, Skolnick P, Weizman A. 1994. Verapamil is not an antidepressant in patients resistant to tricyclic antidepressants. Clin Neuropharmacol 17: 294-297.
2. Anderson IM. 1998. SSRIS versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depress Anxiety 7 (Suppl 1): 11-17.
3. Aszalos A, Thompson K, Yin JJ, Ross DD. 1999. Combinations of P-glycoprotein blockers, verapamil, PSC833, and cremophor act differently on the multidrug resistance associated protein (MRP) and on P-glycoprotein (Pgp). Anticancer Res 19: 1053-1064.
4. Bauer B, Yang X, Hartz AM, et al. 2006. In vivo activation of human pregnane X receptor tightens the blood-brain barrier to methadone through P-glycoprotein up-regulation. Mol Pharmacol 70: 1212-1219.
5. Brown RC, Davis TP. 2002. Calcium modulation of adherens and tight junction function: a potential mechanism for blood-brain barrier disruption after stroke. Stroke 33: 1706-1711.
6. Cohen C, Perrault G, Sanger DJ. 1997. Assessment of the antidepressant-like effects of L-type voltage-dependent channel modulators. Behav Pharmacol 8: 629-638.
7. Connor TJ, Leonard BE. 2004. Biological Markers of Depression Handbook of Experimental Pharmacology. Springer Verlag: New York; 117-148.
8. Daniel W, Danek L, Janczar L, Nocon H, Melzacka M. 1991. Regional distribution of imipramine, desipramine and specific [3H] desipramine binding sites in the rat brain after acute and chronic treatment with imipramine. J Pharm Pharmacol 43: 31-315.
9. De Vry J, Fritze J, Post RM. 1997. The management of coexisting depression in patients with dementia: potential of calcium channel antagonists. Clin Neuropharmacol 20: 22-35.
10. Dinan T, Siggins L, Scully P, O'Brien S, Ross P, Stanton C. 2008. Investigating the inflammatory phenotype of major depression: Focus on cytokines and polyunsaturated fatty acids. J Psychiatr Res. 43: 471-476.
11. Ejsing TB, Linnet K. 2005. Influence of P-glycoprotein inhibition on the distribution of the tricyclic antidepressant nortriptyline over the blood-brain barrier. Hum Psychopharmacol 20: 149-153.
12. Fava M, Davidson KG. 1996. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 19: 179-200.
13. Frahnert C, Rao ML, Grasmader K. 2003. Analysis of eighteen antidepressants, four atypical antipsychotics and active metabolites in serum by liquid chromatography: a simple tool for therapeutic drug monitoring. J Chromatogr B Analyt Technol Biomed Life Sci 794: 35-47.
14. Gillman PK. 2007. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol 151: 737-748.
15. Greden JF. 2002. Unmet need: what justifies the search for a new antidepressant? J Clin Psychiatry 63 (Suppl 2): 3-7.
16. Harkin A, Connor TJ, Mulrooney J, Kelly JP, Leonard BE. 2001. Prior exposure to methylenedioxyamphetamine (MDA) induces serotonergic loss and changes in spontaneous exploratory and amphetamine-induced behaviors in rats. Life Sci 68: 1367-1382.
17. Hennessy M, Kelleher D, Spiers JP, et al. 2002. St Johns wort increases expression of P-glycoprotein: implications for drug interactions. Br J Clin Pharmacol 53: 75-82.
18. Hermann DJ, Krol TF, Dukes GE, et al. 1992. Comparison of verapamil, diltiazem, and labetalol on the bioavailability and metabolism of imipramine. J Clin Pharmacol 32: 176-183.
19. Ho EA, Piquette-Miller M. 2006. Regulation of multidrug resistance by proinflammatory cytokines. Curr Cancer Drug Targets 6: 295-311.
20. Kusuhara H, Sugiyama Y. 2001a. Efflux transport systems for drugs at the blood-brain barrier and blood-cerebrospinal fluid barrier (Part 1). Drug Discov Today 6: 150-156.
21. Kusuhara H, Sugiyama Y. 2001b. Efflux transport systems for drugs at the blood-brain barrier and blood-cerebrospinal fluid barrier (Part 2). Drug Discov Today 6: 206-212.
22. Kwan P, Sills GJ, Butler E, Gant TW, Brodie MJ. 2003. Differential expression of multidrug resistance genes in naive rat brain. Neurosci Lett 339: 33-36.
23. Kwan P, Sills GJ, Butler E, Gant TW, Meldrum BS, Brodie MJ. 2002. Regional expression of multidrug resistance genes in genetically epilepsy-prone rat brain after a single audiogenic seizure. Epilepsia 43: 1318-1323.
24. Loscher W. 2005. Mechanisms of drug resistance. Epileptic Disord 7 (Suppl 1): S3-9.
25. Loscher W, Potschka H. 2005a. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx 2: 86-98.
26. Loscher W, Potschka H. 2005b. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog Neurobiol 76: 22-76.
27. Norsted E, Gomuc B, Meister B. 2008. Protein components of the blood-brain barrier (BBB) in the mediobasal hypothalamus. J Chem Neuroanat. 36: 107-121.
28. Pardridge WM. 2005. The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2: 3-14.
29. Pariante CM, Thomas SA, Lovestone S, Makoff A, Kerwin RW. 2004. Do antidepressants regulate how cortisol affects the brain? Psychoneuroendocrinology 29: 423-447.
30. Schinkel AH. 1999. P-Glycoprotein, a gatekeeper in the blood-brain barrier. Adv Drug Deliv Rev 36: 179-194.
31. Schinkel AH, Jonker JW. 2003. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 55: 3-29.
32. Seegers U, Potschka H, Loscher W. 2002. Expression of the multidrug transporter P-glycoprotein in brain capillary endothelial cells and brain parenchyma of amygdala-kindled rats. Epilepsia 43: 675-684.
33. Steffens DC, Krishnan KR, Helms MJ. 1997. Are SSRIs better than TCAs? Comparison of SSRIs and TCAs: a meta-analysis. Depress Anxiety 6: 10-18.
34. Sukhai M, Piquette-Miller M. 2000. Regulation of the multidrug resistance genes by stress signals. J Pharm Pharm Sci 3: 268-280.
35. Summers MA, Moore JL, McAuley JW. 2004. Use of verapamil as a potential P-glycoprotein inhibitor in a patient with refractory epilepsy. Ann Pharmacother 38: 1631-1634.
36. Taragano FE, Allegri R, Vicario A, Bagnatti P, Lyketsos CG. 2001. A double blind, randomized clinical trial assessing the efficacy and safety of augmenting standard antidepressant therapy with nimodipine in the treatment of 'vascular depression'. Int J Geriatr Psychiatry 16: 254-260.
37. Taragano FE, Bagnatti P, Allegri RF. 2005. A double-blind, randomized clinical trial to assess the augmentation with nimodipine of antidepressant therapy in the treatment of 'vascular depression'. Int Psychogeriatr 17: 487-498.
38. Thomas H, Coley HM. 2003. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 10: 159-165.
39. Uhr M, Steckler T, Yassouridis A, Holsboer F. 2000. Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption. Neuropsychopharmacology 22: 380-387.
40. Uhr M, Tontsch A, Namendorf C, et al. 2008. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron 57: 203-209.
41. Volk HA, Potschka H, Loscher W. 2004. Increased expression of the multidrug transporter P-glycoprotein in limbic brain regions after amygdala-kindled seizures in rats. Epilepsy Res 58: 67-79.
42. Wang JS, Ruan Y, Taylor RM, Donovan JL, Markowitz JS, DeVane CL. 2004a. The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein. Int J Neuropsychopharmacol 7: 415-419.
43. Wang JS, Ruan Y, Taylor RM, Donovan JL, Markowitz JS, DeVane CL. 2004b. Brain penetration of methadone (R)- and (S)-enantiomers is greatly increased by P-glycoprotein deficiency in the blood-brain barrier of Abcb1a gene knockout mice. Psychopharmacology (Berl) 173: 132-138.
44. Zhou S, Chan E, Lim LY, et al. 2004. Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4. Curr Drug Metab 5: 415-442.